Latest Announcements

BSE & NSE corporate filings with AI summaries

BSECompany UpdateFundraise13 Aug 2026

Jattashankar Industries Ltd

Statement of Deviation/Variations for the Quarter ended 30th June 2026

Jattashankar Industries Ltd has filed a statement of deviation/variations for the quarter ended June 30, 2026, related to the utilization of proceeds from the preferential issue of convertible warrants. The company has received ₹23,14,41,985 towards the allotment of convertible equity share warrants and tranche consideration from allottees. There is no deviation/variations in the use of funds raised.

Read more →📎 1 attachment
BSECompany UpdateFundraise13 Aug 2026

Jet Freight Logistics Ltd

Pursuant to Regulation 32 of the SEBI Listing Regulation 2015, Please find enclosed, the statement of deviation and variation in the use of the issue proceeds raised through preferential ....

Jet Freight Logistics Ltd has filed a statement of deviation or variation in the use of proceeds raised through a preferential issue of warrants, confirming that there is no deviation or variation in the use of funds for the quarter ended June 30, 2026.

Read more →📎 1 attachment
BSECompany UpdateFundraise13 Aug 2026

Bank of Baroda

Raising of Senior Unsecured Fixed Rate Reg S Bond

Bank of Baroda has concluded the issuance of Senior Unsecured Fixed Rate Notes amounting to USD 400.00 Mn and USD 300 Mn, with maturities of 3 years and 5 years, respectively, at coupons of 5.114% p.a. and 5.318% p.a. These bonds will be listed on Singapore Stock Exchange, India INX, and NSE-IX Exchange Gift city.

Read more →📎 1 attachment
BSECompany UpdateFundraise13 Aug 2026

JOJO Ltd

Reg 32

JOJO Ltd has filed a statement of deviation under Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirming that there is no deviation or variation in the utilization of proceeds from the preferential issue of convertible warrants.

Read more →📎 1 attachment
BSECompany UpdateFundraise13 Aug 2026

Novelix Pharmaceuticals Ltd

Submission of Statement of Deviation & Variation

Novelix Pharmaceuticals Ltd submitted a statement of deviation and variation as per SEBI (Listing Obligation and Disclosure Requirements) 2015 for the quarter ended 30th June, 2026. The company has raised funds to meet long-term funding requirements, including working capital and general corporate purposes, to support its future growth plan.

Read more →📎 1 attachment
← PreviousPage 132 of 177Next →